Articles Archives - Page 101 of 749

WednesdayJul 24, 2024 9:45 am

SenesTech Inc.’s (NASDAQ: SNES) Evolve(TM) – Offering Sustainable and Humane Solution to NYC’s Rat Problem

New York City has received lots of backlash, mainly from People for the Ethical Treatment of Animals (“PETA”), for its approach to addressing its rat problem Its approach, so far, has been characterized by the use of traps, poisons, and its “Trash Revolution” program, all of which have been unsustainable SenesTech, a rodent fertility control product provider, through its flagship Evolve(TM) product, offers an alternative that could potentially eliminate the entire rodent population in 12 to 18 months This solution avoids the adverse effects of the use of poisons, both to humans and other animals, and offers a sustainable, more…

WednesdayJul 24, 2024 9:00 am

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration

Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a high unmet medical need Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model Age-related macular degeneration (“AMD”) is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part of the retina, known as the macula. This disease significantly impacts the quality of life, making it…

TuesdayJul 23, 2024 9:45 am

Annovis Bio Inc. (NYSE: ANVS) Announces New Executive Team Members

The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”), is thrilled to welcome four seasoned professionals to its executive team. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, said the company was delighted to have this strong group of individuals join…

TuesdayJul 23, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Presents Updates on CNM-Au8(R) at Emerging Growth Conference 73 – Biotech Feature

CNM-Au8(R) works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health Clene has conducted several clinical trials to evaluate the safety and efficacy of CNM-Au8 in neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) The global ALS treatment market is expected to grow significantly, driven by the increasing prevalence of the disease among the aging population Clene has submitted a briefing book to the FDA to seek feedback on a potential pathway for accelerated approval for CNM-Au8 to treat ALS Clene (NASDAQ: CLNN), a biopharmaceutical company, is at the forefront of transforming the treatment of neurodegenerative…

MondayJul 22, 2024 9:45 am

ECGI Holdings Inc. (ECGI) Makes ‘Bold Step Forward’ with Appointment of AI and ML Expert to Board of Advisors

ECGI Holdings, a diversified holding company with a unique portfolio encompassing viticulture, luxury fashion, and hospitality, recently appointed Mandeep Singh, an AI and machine learning expert, to its Board of Advisors Singh’s addition is part of the company’s preparations for the launch of a new line of apparel under Pacific Saddlery’s Allon brand AI provides confidence in size selection, minimizing returns, and better measurement for options, supporting easier upsells Singh will help Pacific Saddlery evaluate and implement technologies to leverage AI precise body measurement solutions to provide personalized fit recommendations In addition, Singh is expected to leverage his experience to…

MondayJul 22, 2024 9:00 am

D-Wave Quantum Inc. (NYSE: QBTS) Adds Second Annealing Quantum Computer in the U.S. and Unveils New Hybrid Quantum Solver

D-Wave introduced its new hybrid quantum solver designed to tackle previously intractable workforce, manufacturing, and logistics optimization problems at its Qubits 2024 conference The new hybrid solver is expected to have a positive impact on a variety of business processes, particularly in workforce, manufacturing, and logistics optimization D-Wave is also deploying a second U.S.-based Advantage(TM) quantum computer at Davidson Technologies’ global headquarters, accessible to D-Wave customers in select countries via D-Wave’s Leap(TM) quantum cloud service D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, continues to make strides in the development and deployment of quantum computing…

FridayJul 19, 2024 9:45 am

SuperCom Ltd.’s (NASDAQ: SPCB) Latest $2.9 Million Government EM Contract Shows Continuing Appeal of its Technology

Electronic monitoring (“EM”) technology developer SuperCom Ltd. recently reported a new contract with European government clients for its flagship product, its third such contract secured within a three-month period SuperCom’s business with European governments that are seeking its EM technology solutions amounts to over $11 million in new orders since April SuperCom’s flagship EM PureSecurity Suite products provide monitoring solutions that are chiefly being used as an alternative to incarceration The EM market is growing as criminal justice officials increasingly seek alternatives to incarceration as a means of cutting costs while simultaneously benefitting society through reduced recidivism and increased productive…

FridayJul 19, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Announces New Data From Phase III Study of Buntanetap for Early Parkinson’s Disease

The study shows buntanetap is effective in enhancing both motor and cognitive functions, as well as non-motor activities in Parkinson’s Disease patients Following the announcement of these positive results, the company’s stock price surged by 76% The data revealed that while 12% of Parkinson’s Disease patients showed cognitive decline, buntanetap not only halted this decline but also led to improvements Annovis held a webcast to go over the results in more depth, which is available for replay on the company’s website Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s…

ThursdayJul 18, 2024 10:30 am

Nickel Rush Heats Up in Canada: Opening Doors for Companies Like Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) as Canada Eyes a Top Spot Among Global Producers

Nickel demand is expected to grow at a continually accelerating rate over the coming years and decades By 2040, use in batteries will command 41% of total nickel usage, up from just 7% in 2021 Nickel is considered one of the most strategically vulnerable critical metals in North America or the west Like Canada’s Critical Minerals Infrastructure Fund (“CMIF”), the west has been making increasing efforts to encourage critical metal exploration and extraction Fathom is developing two highly prospective projects in Canada’s Trans-Hudson Corridor in Saskatchewan Fathom has received a new drill permit that allows for up to 60 drill…

ThursdayJul 18, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Announces Plan to Submit Briefing Book to FDA Preceding Type C Interaction

Clene plans to submit a briefing book to the U.S. Food and Drug Administration by July 13 as Part of Overall Process to Support Approval for CNM-Au8(R) for Treatment of ALS Type C interaction is aimed at obtaining FDA feedback on the potential pathway for a new drug application for CNM-Au8 as a treatment for ALS via the accelerated approval process The briefing book includes new post-hoc analyses of data from completed clinical trials and addresses comments made by the FDA during a previous meeting in late 2023 Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a…

Site Search

Company Search

Category: Articles